Ascentage Approved to Start China Trial of Apoptosis Candidate for Pancreatic Cancer
publication date: Feb 24, 2020
Ascentage Pharma of Suzhou is approved to start a China Phase Ib/II clinical trial of APG-1387, a novel small molecule IAP inhibitor that induces apoptosis. APG-1387 will be tested together with chemotherapy in patients with advanced pancreatic cancer. In preclinical tests, the candidate inhibited the growth of tumor cells, either as a monotherapy or in combination with targeted agents or chemotherapies. APG-1387 is the first IAP inhibitor to start China clinical trials. Ascentage develops novel therapies for cancers, chronic hepatitis B and age-related diseases. More details....
Stock Symbol: (HK: 6855)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.